Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/102857METHODS FOR MANAGEMENT OF WEIGHT
WO 28.05.2020
Int.Class A61K 31/5517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
Appl.No PCT/AU2019/051284 Applicant THE UNIVERSITY OF SYDNEY Inventor MCGREGOR, Iain Stewart
Disclosed herein are methods for causing weight loss, for managing weight, and for suppressing an appetite for food in a subject, and methods for reducing the consumption of food by a subject by administering the compounds, or pharmaceutically acceptable salts or prodrugs thereof, of the invention.
2.WO/2020/103817TGF-βR1 INHIBITOR AND USE THEREOF
WO 28.05.2020
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/CN2019/119413 Applicant NANJING SANHOME PHARMACEUTICAL CO., LTD. Inventor WANG, Yong
The present invention belongs to the field of medicinal chemistry, and relates to a class of compounds as a TGF-βR1 inhibitor and the use thereof. Specifically, provided in the present invention are a compound shown in formula I, or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method therefor and a pharmaceutical composition containing these compounds, and the use of these compounds or compositions for treating and/or preventing TGF-βR1-related diseases, such as cancers, tissue proliferative diseases, fibrosis and inflammatory diseases. The compounds of the present invention exhibit significant inhibitory activity on TGF-βR1 kinases, and have very strong potential to be therapeutic agents for TGF-βR1-related diseases. (I)
3.WO/2020/103897HETEROCYCLIC FUSED PYRIMIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
WO 28.05.2020
Int.Class A61K 31/7064
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
Appl.No PCT/CN2019/119899 Applicant SHANGHAI DE NOVO PHARMATECH CO., LTD. Inventor ZHAO, Zhiming
A heterocyclic fused pyrimidine derivative, a pharmaceutical composition thereof, and an application thereof. A heterocyclic fused pyrimidine derivative (I), and an isomer, prodrug, stable isotope derivative, or pharmaceutically acceptable salts thereof have the following structure. The heterocyclic fused pyrimidine derivative can inhibit the ATR level well both in vivo and in vitro. Furthermore, the heterocyclic fused pyrimidine derivative can be also used for effectively treating diseases caused by the abnormal ATR level such as cancer.
4.WO/2020/104267α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
WO 28.05.2020
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/EP2019/081134 Applicant BAYER AKTIENGESELLSCHAFT Inventor DELBECK, Martina
The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted bipiperidinyl derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which Y is a group (A) or (B).
5.WO/2020/104657NLRP3 INHIBITORS
WO 28.05.2020
Int.Class A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
Appl.No PCT/EP2019/082231 Applicant INFLAZOME LIMITED Inventor COOPER, Matthew
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.
6.WO/2020/104697STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE
WO 28.05.2020
Int.Class C07H 17/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
Appl.No PCT/EP2019/082331 Applicant VAXXILON AG Inventor EMMADI, Madhu
The present invention relates to a synthetic saccharide of general formula (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.
7.WO/2020/104837ORAL TOPIRAMATE SUSPENSION FORMULATIONS WITH EXTENDED SHELF STABILITY AND ENHANCED BIOAVAILABILITY
WO 28.05.2020
Int.Class A61K 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
Appl.No PCT/IB2018/059194 Applicant ROSEMONT PHARMACEUTICALS LIMITED Inventor MUSTAFA, Tajamal
The present application relates generally to pharmaceutical compositions comprising a pharmaceutically effective amount of topiramate particles dispersed in suspension, wherein the composition is suitable for oral delivery. The present application also relates generally to novel cold-chain stable formulations of oral liquid suspension dosage forms containing topiramate and a process for producing said oral liquid suspension dosage forms. Also disclosed are improved analytical methods for assaying complex drug formulations containing sulfamate-substituted monosaccharides.
8.WO/2020/104987COMPOSITION FOR USE IN THE PREVENTION AND/OR SYMPTOMATIC TREATMENT OF IRRITABLE BOWEL SYNDROME
WO 28.05.2020
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
Appl.No PCT/IB2019/060029 Applicant NEILOS S.R.L. Inventor DI MAIO, Umberto
A synergistic composition of naturally occurring active ingredients is described, which has proved particularly effective in the treatment and/or prevention of irritable bowel syndrome. The composition of the invention includes the synergistic combination of butyric acid or a salt thereof and Tamarindus indica extract.
9.WO/2020/105027METHOD AND COMPOSITION FOR PREVENTING OR TREATING DIABETIC AND NON-DIABETIC KETOACIDOSIS USING GLYCEROL
WO 28.05.2020
Int.Class A61K 31/047
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
047having two or more hydroxy groups, e.g. sorbitol
Appl.No PCT/IL2019/051207 Applicant THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) Inventor DVIR, Hay
The present invention provides a pharmaceutical composition and method for preventing or treating diabetic ketoacidosis by administering an effective amount of glycerol, alone or with other agents.
10.WO/2020/106007FILM-COATED TABLET HAVING EXCELLENT MOISTURE-PROOF PROPERTY
WO 28.05.2020
Int.Class A61K 9/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
28Dragees; Coated pills or tablets
Appl.No PCT/KR2019/015824 Applicant KOFITECH CO., LTD. Inventor LEE, Kyoung-Ho
Provided in the present invention is a film-coated tablet having an excellent moisture-proof property and being easily coated. Particularly, the present invention is useful for film-coating of an ingredient having low stability due to high deliquescence, such as choline alfoscerate.